title: Reasons for enucleation after plaque radiotherapy for posterior uveal melanoma. Clinical findings.
abstract: A review of 1019 patients with posterior uveal melanomas who were treated with episcleral plaque radiotherapy showed that 59 (6%) required enucleation of the affected eye. Seventeen of the enucleations were done within 1 year, 30 within 2 years, and 55 within 5 years. The enucleated eyes had been treated with a cobalt-60 plaque in 39 cases, a ruthenium-106 plaque in 13 cases, an iodine-125 plaque in four cases, and an iridium-192 plaque in three cases. The primary reasons for enucleation included tumor regrowth in 30 cases (51%), neovascular glaucoma in 18 (31%), patient request in five (8%), scleral melting in four (7%), painful bullous keratopathy in one (2%), and hemolytic glaucoma in one (2%). The time interval from plaque treatment to eventual enucleation averaged 29 months. Tumor regrowth requiring enucleation was detected clinically an average of 28 months after treatment. In these cases the average radiation dose to the tumor apex was 7700 cGy and to the tumor base 36,000 cGy. Uncontrollable neovascular glaucoma occurred an average of 38 months after plaque radiotherapy and, most commonly, after cobalt-60 plaques were used. Eyes with plaque-induced scleral melting eventually required enucleation after an average of 10 months. In all cases of scleral melting, the tumor was ciliochoroidal.
authors.affiliation: Oncology Service, Wills Eye Hospital, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19105.
authors.forename: C L
authors.initials: CL
authors.lastname: Shields
authors.forename: J A
authors.initials: JA
authors.lastname: Shields
authors.forename: U
authors.initials: U
authors.lastname: Karlsson
authors.forename: A M
authors.initials: AM
authors.lastname: Markoe
authors.forename: L W
authors.initials: LW
authors.lastname: Brady
mesh_terms: D000328:Adult; D000368:Aged; D001918:Brachytherapy; D003316:Corneal Diseases / Q000209:etiology; D015353:Eye Enucleation; D005260:Female; D005901:Glaucoma / Q000209:etiology; D015355:Glaucoma, Neovascular / Q000209:etiology; D006801:Humans; D008297:Male; D008545:Melanoma / Q000532:radiotherapy*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000209:etiology*; D010349:Patient Compliance; D015422:Scleral Diseases / Q000209:etiology; D013997:Time Factors; D014604:Uveal Neoplasms / Q000532:radiotherapy*; D014792:Visual Acuity